This study is evaluating the safety, tolerability, and immune response generated by a single dose of a redesigned bivalent Omicron BA.4/BA.5 study vaccine in children 12-17 years old and adults who have received only 3 prior doses of the Pfizer & BioNTech COMIRNATY® vaccine. About 500 participants will be enrolled in the United States.
We are currently recruiting adults 56 years and older.
An Important Contribution
Receiving a COVID-19 vaccine and booster is still the best strategy for protecting yourself and others from serious illness. However, the level of protection against COVID-19 has been shown to decrease with time, just like it does after natural infection. For this reason, researchers are evaluating if a redesigned version of an investigational vaccine may improve and extend the immune response, particularly against BA.4 and BA.5, two new versions of the Omicron variant that are now responsible for the majority of COVID-19 cases in the United States.
By choosing to volunteer, you will represent others like you - in age, gender, race, ethnicity, and from communities like yours. Including people from all backgrounds will improve the effectiveness of the COVID-19 vaccine for everyone.
Joining a clinical trial is an important and personal decision. Thank you for considering this study.